Clinical trials
General Population (no Specific Condition or Disease) clinical trials
Below are recruiting general population (no specific condition or disease) clinical trials, each written for real people, not researchers. We’re tracking 10,808 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06260059RecruitingPhase 4
Jardiance for adults with congenital heart disease and reduced heart function
This study tests a medicine called Jardiance (an SGLT2 inhibitor) to see if it helps improve heart function in adults with congenital heart disease who have recently experienced a drop in their heart pumping ability. Participants will take the medication alongside standard heart failure treatments.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06260891RecruitingPhase 2
Zinc study for sickle cell disease and bone health
This study tests if taking zinc supplements can improve bone health in people with sickle cell disease. It's for those with certain types of sickle cell disease (SS or S-Beta zero thalassemia) who are not on chronic transfusions or zinc supplements.
Oakland, CaliforniaAges 15–40 - NCT06266442Recruiting
DNA study of M. avium in lung infection
This study looks at the DNA of the bacteria causing your lung infection (Mycobacterium avium) to understand treatment better. It involves analyzing stored samples and may include patients who have been treated before.
Toronto, OntarioAges 18 years+ - NCT06270316RecruitingPhase 1/Phase 2
Gene therapy for classic Fabry disease
This trial tests a new gene therapy called AMT-191 for men with classic Fabry disease who still have symptoms despite standard enzyme replacement therapy. It aims to see if the treatment is safe and can improve symptoms.
Birmingham, AlabamaAges 18–50 - NCT06271590Recruiting
Drug-coated balloon for small heart artery blockages
This trial tests a special balloon coated with a drug (sirolimus) to treat blockages in small heart arteries. If the balloon is successful, it may help keep the artery open without needing a permanent stent.
Gilbert, ArizonaAges 18–80 - NCT06272149RecruitingEarly Phase 1
Gene Therapy for Infants With Type 2 Gaucher Disease
This trial tests a new gene therapy (VGN-R08b) for infants with Type 2 Gaucher disease, a rare genetic condition that affects the brain and body. The goal is to see if the treatment is safe and can help improve symptoms.
Shanghai, Shanghai MunicipalityAges birth–2 years - NCT06275113Recruiting
Prevention program for heart and artery disease
This study tests a prevention program for people who have already had a heart event, stroke, or leg artery blockage. It is designed to help reduce the risk of future heart problems.
Canicattì, AGAges 18 years+ - NCT06278909Recruiting
Nerve stimulation for stubborn anxiety
This study tests a new, non-invasive treatment using mild electrical stimulation on a nerve in your face (trigeminal nerve) to help with anxiety that hasn't improved with other treatments. It aims to see if this approach is safe and helpful for people with generalized anxiety disorder who have not responded to standard medications.
Kingston, OntarioAges 18–65 - NCT06279923RecruitingEarly Phase 1
CAR-T cells for autoimmune diseases
This trial tests a new CAR-T cell therapy that targets two immune proteins (CD19 and BAFF) to treat autoimmune diseases like lupus or scleroderma. It is for people who have not improved with standard treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT06281665RecruitingPhase 4
Aspirin after preeclampsia: the TAP trial
This trial tests whether taking low-dose aspirin after giving birth can help people who had preeclampsia. It aims to see if aspirin can lower the risk of future heart problems.
Pittsburgh, PennsylvaniaAges 18–55 - NCT06283316Recruiting
A registry for alopecia areata treatments
This trial is a registry that collects information from people with alopecia areata who are starting or using body-wide treatments. It helps doctors learn more about how these treatments work in real life.
RotterdamAges 16 years+ - NCT06283966RecruitingPhase 3
Triple inhaler for COPD with heart risk
This study tests a triple-combination inhaler (budesonide, glycopyrronium, and formoterol) to see if it can help protect the heart and lungs in people with COPD who also have heart problems or high risk for them.
Athens, AlabamaAges 40–80 - NCT06286748Recruiting
Beetroot drink and exercise for kidney disease
This study tests if drinking beetroot extract along with a structured exercise program can help people with chronic kidney disease. It looks at whether this combination can improve health and delay the need for more advanced treatments.
Rio de Janeiro, Rio de JaneiroAges 18–65 - NCT06288464Recruiting
Fiber in tube feeding to improve gut health
This trial tests adding fiber to liquid food given through a stoma before stoma reversal surgery. The goal is to see if it helps improve the balance of good bacteria in the gut.
Preston, LancashireAges 18 years+ - NCT06291116RecruitingPhase 2
Safety of rotigotine patch for ADPKD patients
This study tests a skin patch called rotigotine to see if it is safe for people with ADPKD. It may help with blood pressure control, but you cannot have advanced kidney failure or certain other health issues.
AmiensAges 18–60 - NCT06294028Recruiting
Ablation vs Defibrillator for Well-Tolerated Fast Heartbeat
This study compares two treatments for a fast heartbeat called ventricular tachycardia in people with prior heart attacks and relatively preserved heart function: one uses heat energy (ablation) to fix the electrical problem, and the other places an implantable defibrillator that shocks the heart to restore normal rhythm. The goal is to find which approach works better for people whose symptoms are well-tolerated.
Toulouse, FranceAges 18–90 - NCT06295120RecruitingPhase 4
Finding the best antibiotic course for pneumonia in adults
This trial is testing how many days of antibiotics are best for adults with pneumonia who are treated by their regular doctor (not in a hospital). The goal is to find the shortest effective treatment to reduce side effects and antibiotic resistance.
GistrupAges 18 years+ - NCT06295614Recruiting
ARC-IM therapy for walking problems in Parkinson's
This study tests a new therapy called ARC-IM to help with walking issues like freezing or balance problems in people with Parkinson's. It aims to see if the therapy is safe and can improve movement.
Lausanne, Canton of VaudAges 18 years+ - NCT06296472Recruiting
Comparing hand therapy for De Quervain's disease after steroid injection
This trial compares two types of hand therapy for patients with De Quervain's disease, a painful condition affecting the thumb tendons. One group receives standard hand therapy, while the other gets a new approach after an ultrasound-guided steroid injection.
BolognaAges 18 years+ - NCT06297096RecruitingPhase 3
Testing a two-drug combo for lung scarring in scleroderma
This study tests whether a combination of two drugs, nintedanib and tocilizumab, can help people with systemic sclerosis (a condition that causes skin and organ hardening) who also have lung scarring (interstitial lung disease). The goal is to find a treatment that can slow down the disease.
Warsaw, Masovian VoivodeshipAges 18–74 - NCT06297590RecruitingPhase 1
First human study of a new Alzheimer's drug
This study tests an experimental drug (LY3954068) for people with early Alzheimer's disease. It aims to see if the drug is safe and may slow memory loss. You'll need a PET scan to measure tau protein in the brain and have a study partner who can help attend appointments.
Maitland, FloridaAges 50–85 - NCT06298188Recruiting
Studying risankizumab in children with Crohn's disease
This study follows children with Crohn's disease who have already started taking risankizumab. It aims to see how well the treatment works in real-world use.
JerusalemAges 6–18 - NCT06298461RecruitingPhase 4
Comparing bowel preps for Crohn's and colitis patients
This trial compares two different bowel preparation solutions (2L-PEG and oral sulfate solution) for people with Crohn's disease or ulcerative colitis who are having a colonoscopy. The goal is to find which preparation works better and is more comfortable for patients with these conditions.
Winnipeg, ManitobaAges 18 years+ - NCT06300541Recruiting
Sarcopenia in inflammatory bowel disease flare-ups
This study looks at how common muscle loss (sarcopenia) is in people with inflammatory bowel disease during a flare-up, and what impact it has. By participating, you may help doctors better understand and treat muscle weakness in IBD.
GothenburgAges 18 years+
Hear when a new General Population (no Specific Condition or Disease) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for general population (no specific condition or disease)?
- Yes. Clin2 currently lists 10,808 recruiting general population (no specific condition or disease) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a general population (no specific condition or disease) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a general population (no specific condition or disease) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.